Stay updated with breaking news from Chris Recknor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
This CMC is a critical part of the biotech's Biologics License Application (BLA) for HIV - the request for permission to commercialize a product
A 12-month analysis of 28 metastatic triple-negative breast cancer patients receiving leronlimab suggests an increase of 3,600% in 12-month...
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Statistically significant 133% faster time to COVID-19 clinical symptoms recovery versus standard of care (SOC)/best supportive care. Statistically significant...
CytoDyn Submits Dose Justification Report to FDA to Begin Overcoming Deficiencies in its BLA for HIV Management works to advance its BLA filing seeking FDA approval for leronlimab as a combination therapy for HIV patients while continuing its evaluation of other potential indications VANCOUVER, Washington, July 01, 2021 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today it has submitted a dose justification re...